跳转至内容
Merck
CN
  • Effect of vitamin D supplementation on orthostatic hypotension: data from the vitamin D in isolated systolic hypertension randomized controlled trial.

Effect of vitamin D supplementation on orthostatic hypotension: data from the vitamin D in isolated systolic hypertension randomized controlled trial.

Journal of hypertension (2014-06-01)
Miles D Witham, Rosemary J G Price, Allan D Struthers, Peter T Donnan, Martina Messow, Alex McConnachie, Ian Ford, Marion E T McMurdo
摘要

Orthostatic hypotension commonly accompanies supine hypertension, and is associated with low 25-hydroxyvitamin D levels. We tested whether high-dose intermittent oral vitamin D therapy could ameliorate orthostatic hypotension in older patients with isolated systolic hypertension. We conducted a subgroup analysis of data from a parallel-group, double-blind, randomized, placebo-controlled trial. Patients aged over 70 years with supine office SBP above 140 mmHg and DBP below 90 mmHg received 100 000 units oral vitamin D3 or matching placebo every 3 months for 1 year. Office supine and standing blood pressure were measured at baseline, and 3, 6, 9 and 12 months, along with arterial stiffness and flow-mediated dilatation of the brachial artery. Of 159 patients randomized to the main trial, 75 patients with orthostatic hypotension at baseline were included in this analysis. The mean age was 78 (SD 5) years, baseline blood pressure was 162/76 mmHg and the mean baseline orthostatic fall in blood pressure on standing was 32/5 mmHg. After adjustment for baseline age, 25-hydroxyvitamin D, SBP and orthostatic fall, the fall in SBP was less in the vitamin D group at 3 months [treatment effect 6 mmHg, 95% confidence interval (CI) 0 to 12], but repeated-measures analysis showed no significant treatment effect (3 mmHg for systolic fall, 95% CI -1 to 8; 1 mmHg for diastolic fall, 95% CI -1 to 3). Twelve months of intermittent, high-dose oral vitamin D3 did not significantly improve orthostatic hypotension in older patients with isolated systolic hypertension.

材料
产品编号
品牌
产品描述

Supelco
胆钙化醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
胆钙化醇, ≥98% (HPLC)
Supelco
胆钙化固醇(维生素 D3), analytical standard
USP
胆钙化醇, United States Pharmacopeia (USP) Reference Standard
Supelco
维生素D3标准液 CRM 溶液, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
胆钙化醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
胆钙化醇, meets USP testing specifications
Sigma-Aldrich
胆钙化醇, analytical standard